Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005618 · ClinicalTrials.gov registry record · Phase 2
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005618: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00005618 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005618, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory chronic myelogenous leukemia.
Interventions
- DRUG arsenic trioxide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-02 |
| Est. Completion | 2004-03 |
| Phase | Phase 2 |
What the finished NCT00005618 record still lists
NCT00005618 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which arsenic trioxide is the first listed.
NCT00005618 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005618 about?
NCT00005618 is a clinical study titled "Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory chronic myelogenous leukemia.
What is the current status of trial NCT00005618?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-02. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00005618?
The interventions under investigation include: arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT00005618?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia